News About: Pharm. Industry
Recent SARS fear batters drug exports
The domestic pharmaceutical industry raised a serious concern about the drug export to China critically hampered by the outbreak of SARS mainly due to remarkable declined drug consumption in China and the logistic dif...
Marketing strategies to segment by seasonal diseases.
The pharmaceutical companies are pushing their marketing promotional campaigns over the items for the seasonal market demand, such as yellow dusts blown from the China desert, SARS and allergenic pollens.
The indus...
Pharmaceutical trade balance swings positive
Korea's pharmaceutical trade imbalance has been markedly improved for three straight months this year, as the on-year growth rate of pharmaceutical exports exceed that of imports by two times, according to sta...
Industry to strengthen OTC drug sales and public advertising.
The domestic pharmaceutical industry tried to achieve this year ambitious sales target by strengthening the OTC new product development.
Their forecasted sales targets last year were achieved merely by 80 to 90% of...
Products for children's stature growth on hot competition.
A lot of nutritional supplement food products for the children's stature growth are now in market with severe competition, starting "Long Keybon" developed by Chongkundang in 1999 formulated with some herbal drugs, th...
KPMA to reject the lowest actual transaction pricing system.
The KPMA admitted with a whopping backlash that the NHI drug price slashes applying the post management system for the lowest actual transaction drug price ultimately caused the pharmaceutical industry to collapse.
...
Government urged to promote R&D new drug projects
Current estimates put the average research and development cost in Korea of a wholly new drug in the range of 10.6 billion won with the relevant period of 8.9 years, according to the list revealed by the Korea...
Local drug makers brace for severe damage
Korea's drug makers are bracing for a prolonged downdraft in the domestic pharmaceutical market following the government's ex post facto drug pricing inspection on 4,300 items from 190 medical institutions, which have...
Domestic antihypertensive market heavily contested
Witnessing more than 20 percent in sales growth year-on-year, the domestic antihypertensive market in 2002 was estimated to be about 600 million won with 170 items and expanded by 43 percent as of the end of last year...
Multinational drug firms post brisk sales
Foreign drug manufacturers in the local market have been on the receiving end of a sales bonanza since medical reforms were instituted three years ago, whereas Korean drug manufacturers are on edge.
Rep. Ki...
